注意:因業務調整,暫不接受個人委托測試望見諒。
品系全名:C57BL/6JSmoc-Cd274em1(hPD-L1)Smoc
目錄號:NM-HU-00062
品系狀態:活體
通過同源重組,將小鼠基因Cd274進行人源化修飾。與此相似的品系還有hPD-L1(2)(NM-HU-190039),詳細信息請咨詢技術顧問。
基因名:Cd274
基因曾用名:B7h1, Pdl1, Pdcd1l1,Pdcd1lg1, A530045L16Rik
NCBI ID:60533
MGI ID:1926446
Ensembl ID:ENSMUSG00000016496
Pubmed:Cd274
人類同源基因:CD274
Fig1.?Expression of PD-L1 in the spleen lymphocytes collected from homozygous humanized PD-L1 mice and wild-type mice is detected by FACS. The results showed that the expression of human PD-L1 can be detected in both T cells and B cells collected from the spleen of homozygous humanized PD-L1 mice. (Completed in collaboration with CrownBio)
Fig2. Immunotype in blood , spleen and bone marrow in hPD-L1 mice.
Fig3. Immunotype in blood in hPD-L1 mice.
Fig4. Immunotype in spleen in hPD-L1 mice.
Fig5. Immunotype in bone marrow in hPD-L1 mice.
Fig6. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized PD-L1 mice. Homozygous humanized PD-L1 mice were inoculated with MC38 colon cancer cells (expressing human PDL1 rather than murine PD-L1). After the tumors grew to 100 mm3, the animals were randomly assigned into a control group and a treatment group (n=5). The results showed: The antibodies targeting human PD-L1 were associated with a very significant anti-tumor effect (TGI: tumor growth inhibition, p < 0.001), demonstrating that the humanized PD-L1 mice are a good in vivo model for validating the efficacy of antibodies targeting human PD-L1.
hCD274(BALB/c)品系名:BALB/cAnSmoc-Cd274em1(hCD274)Smoc品系狀態:在研 | 目錄號:NM-HU-230465
hPD-L1(BALB/c,2)品系名:BALB/cAnSmoc-Cd274em2(hPD-L1)Smoc品系狀態:在研 | 目錄號:NM-HU-230474
hPD-L1/hCD28品系名:C57BL/6JSmoc-Cd274em1(hPD-L1)Cd28em2(hCD28)Smoc品系狀態:活體 | 目錄號:NM-HU-210019
Cd274-Flox品系名:C57BL/6JSmoc-Cd274em1(flox)Smoc品系狀態:活體 | 目錄號:NM-CKO-200298
hPD-L1(2)品系名:C57BL/6JSmoc-Cd274em2(hPD-L1)Smoc品系狀態:活體 | 目錄號:NM-HU-190039
1.具體的試驗周期以工程師告知的為準。
2.文章中的圖片或者標準以及具體的試驗方案僅供參考,因為每個樣品和項目都有所不同,所以最終以工程師告知的為準。
3.關于(樣品量)的需求,最好是先咨詢我們的工程師確定,避免不必要的樣品損失。
4.加急試驗周期一般是五個工作日左右,部分樣品有所差異
5.如果對于(hPD-L1)還有什么疑問,可以咨詢我們的工程師為您一一解答。